How does initial treatment choice affect short-term and long-term costs for clinically localized prostate cancer?

Claire Snyder, Kevin Frick, Amanda L. Blackford, Robert J. Herbert, Bridget A. Neville, Michael A Carducci, Craig C. Earle

Research output: Contribution to journalArticle

Abstract

Background. Data regarding costs of prostate cancer treatment are scarce. This study investigates how initial treatment choice affects short-term and long-term costs. Methods. This retrospective, longitudinal cohort study followed prostate-cancer cases diagnosed in 2000 for 5 years using the Surveillance, Epidemiology, and End Results (SEER)-Medicare database. Men age ≥66 years, in Medicare fee for service, diagnosed with clinically localized prostate cancer in 2000 while residing in a SEER region, were matched to noncancer controls using age, sex, race, region, comorbidity, and survival. On the basis of treatment received during the first 9 months postdiagnosis, patients were assigned to watchful waiting, radiation, hormonal therapy, hormonal + radiation, and surgery (may have received other treatments). Incremental costs for prostate cancer were the difference in costs for prostate cancer cases versus matched controls. Costs were divided into initial treatment (months -1 to 12), long-term (each 12 months thereafter), and total (months -1 to 60). Sensitivity analyses excluded the last 12 months of life. Results. A total of 13,769 prostate-cancer cases were matched to 13,769 noncancer controls. Watchful waiting had the lowest initial treatment ($4270) and 5-year total costs ($9130). Initial treatment costs were highest for hormonal + radiation ($17,474) and surgery ($15,197). At $26,896, 5-year total costs were highest for hormonal therapy only followed by hormonal + radiation ($25,097) and surgery ($19,214). After excluding the last 12 months of life, total costs were highest for hormonal + radiation ($23,488) and hormonal therapy ($23,199). Conclusions. Patterns of costs vary widely based on initial treatment. These data can inform patients and clinicians considering treatment options and policy makers interested in patterns of costs. Cancer 2010. © 2010 American Cancer Society. This study examined the short-term and long-term costs of prostate cancer treatment based on the initial treatment received for 13,769 men diagnosed with clinically localized prostate cancer. Patterns of costs varied widely based on initial treatment; 5-year total costs were $26,896 for hormonal therapy only, $25,097 for hormonal therapy plus radiation, $19,214 for surgery, $15,589 for radiation only, and $9130 for watchful waiting.

Original languageEnglish (US)
Pages (from-to)5391-5399
Number of pages9
JournalCancer
Volume116
Issue number23
DOIs
StatePublished - Dec 1 2010

Fingerprint

Prostatic Neoplasms
Costs and Cost Analysis
Watchful Waiting
Therapeutics
Radiation
Medicare
Epidemiology
Radiotherapy
Fee-for-Service Plans
Administrative Personnel
Health Care Costs
Longitudinal Studies
Comorbidity
Cohort Studies
Databases
Survival

Keywords

  • costs
  • health services
  • patterns of care
  • prostate cancer
  • treatment

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

How does initial treatment choice affect short-term and long-term costs for clinically localized prostate cancer? / Snyder, Claire; Frick, Kevin; Blackford, Amanda L.; Herbert, Robert J.; Neville, Bridget A.; Carducci, Michael A; Earle, Craig C.

In: Cancer, Vol. 116, No. 23, 01.12.2010, p. 5391-5399.

Research output: Contribution to journalArticle

Snyder, Claire ; Frick, Kevin ; Blackford, Amanda L. ; Herbert, Robert J. ; Neville, Bridget A. ; Carducci, Michael A ; Earle, Craig C. / How does initial treatment choice affect short-term and long-term costs for clinically localized prostate cancer?. In: Cancer. 2010 ; Vol. 116, No. 23. pp. 5391-5399.
@article{bdc53c58b0c148478dd1532151c20ee2,
title = "How does initial treatment choice affect short-term and long-term costs for clinically localized prostate cancer?",
abstract = "Background. Data regarding costs of prostate cancer treatment are scarce. This study investigates how initial treatment choice affects short-term and long-term costs. Methods. This retrospective, longitudinal cohort study followed prostate-cancer cases diagnosed in 2000 for 5 years using the Surveillance, Epidemiology, and End Results (SEER)-Medicare database. Men age ≥66 years, in Medicare fee for service, diagnosed with clinically localized prostate cancer in 2000 while residing in a SEER region, were matched to noncancer controls using age, sex, race, region, comorbidity, and survival. On the basis of treatment received during the first 9 months postdiagnosis, patients were assigned to watchful waiting, radiation, hormonal therapy, hormonal + radiation, and surgery (may have received other treatments). Incremental costs for prostate cancer were the difference in costs for prostate cancer cases versus matched controls. Costs were divided into initial treatment (months -1 to 12), long-term (each 12 months thereafter), and total (months -1 to 60). Sensitivity analyses excluded the last 12 months of life. Results. A total of 13,769 prostate-cancer cases were matched to 13,769 noncancer controls. Watchful waiting had the lowest initial treatment ($4270) and 5-year total costs ($9130). Initial treatment costs were highest for hormonal + radiation ($17,474) and surgery ($15,197). At $26,896, 5-year total costs were highest for hormonal therapy only followed by hormonal + radiation ($25,097) and surgery ($19,214). After excluding the last 12 months of life, total costs were highest for hormonal + radiation ($23,488) and hormonal therapy ($23,199). Conclusions. Patterns of costs vary widely based on initial treatment. These data can inform patients and clinicians considering treatment options and policy makers interested in patterns of costs. Cancer 2010. {\circledC} 2010 American Cancer Society. This study examined the short-term and long-term costs of prostate cancer treatment based on the initial treatment received for 13,769 men diagnosed with clinically localized prostate cancer. Patterns of costs varied widely based on initial treatment; 5-year total costs were $26,896 for hormonal therapy only, $25,097 for hormonal therapy plus radiation, $19,214 for surgery, $15,589 for radiation only, and $9130 for watchful waiting.",
keywords = "costs, health services, patterns of care, prostate cancer, treatment",
author = "Claire Snyder and Kevin Frick and Blackford, {Amanda L.} and Herbert, {Robert J.} and Neville, {Bridget A.} and Carducci, {Michael A} and Earle, {Craig C.}",
year = "2010",
month = "12",
day = "1",
doi = "10.1002/cncr.25517",
language = "English (US)",
volume = "116",
pages = "5391--5399",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "23",

}

TY - JOUR

T1 - How does initial treatment choice affect short-term and long-term costs for clinically localized prostate cancer?

AU - Snyder, Claire

AU - Frick, Kevin

AU - Blackford, Amanda L.

AU - Herbert, Robert J.

AU - Neville, Bridget A.

AU - Carducci, Michael A

AU - Earle, Craig C.

PY - 2010/12/1

Y1 - 2010/12/1

N2 - Background. Data regarding costs of prostate cancer treatment are scarce. This study investigates how initial treatment choice affects short-term and long-term costs. Methods. This retrospective, longitudinal cohort study followed prostate-cancer cases diagnosed in 2000 for 5 years using the Surveillance, Epidemiology, and End Results (SEER)-Medicare database. Men age ≥66 years, in Medicare fee for service, diagnosed with clinically localized prostate cancer in 2000 while residing in a SEER region, were matched to noncancer controls using age, sex, race, region, comorbidity, and survival. On the basis of treatment received during the first 9 months postdiagnosis, patients were assigned to watchful waiting, radiation, hormonal therapy, hormonal + radiation, and surgery (may have received other treatments). Incremental costs for prostate cancer were the difference in costs for prostate cancer cases versus matched controls. Costs were divided into initial treatment (months -1 to 12), long-term (each 12 months thereafter), and total (months -1 to 60). Sensitivity analyses excluded the last 12 months of life. Results. A total of 13,769 prostate-cancer cases were matched to 13,769 noncancer controls. Watchful waiting had the lowest initial treatment ($4270) and 5-year total costs ($9130). Initial treatment costs were highest for hormonal + radiation ($17,474) and surgery ($15,197). At $26,896, 5-year total costs were highest for hormonal therapy only followed by hormonal + radiation ($25,097) and surgery ($19,214). After excluding the last 12 months of life, total costs were highest for hormonal + radiation ($23,488) and hormonal therapy ($23,199). Conclusions. Patterns of costs vary widely based on initial treatment. These data can inform patients and clinicians considering treatment options and policy makers interested in patterns of costs. Cancer 2010. © 2010 American Cancer Society. This study examined the short-term and long-term costs of prostate cancer treatment based on the initial treatment received for 13,769 men diagnosed with clinically localized prostate cancer. Patterns of costs varied widely based on initial treatment; 5-year total costs were $26,896 for hormonal therapy only, $25,097 for hormonal therapy plus radiation, $19,214 for surgery, $15,589 for radiation only, and $9130 for watchful waiting.

AB - Background. Data regarding costs of prostate cancer treatment are scarce. This study investigates how initial treatment choice affects short-term and long-term costs. Methods. This retrospective, longitudinal cohort study followed prostate-cancer cases diagnosed in 2000 for 5 years using the Surveillance, Epidemiology, and End Results (SEER)-Medicare database. Men age ≥66 years, in Medicare fee for service, diagnosed with clinically localized prostate cancer in 2000 while residing in a SEER region, were matched to noncancer controls using age, sex, race, region, comorbidity, and survival. On the basis of treatment received during the first 9 months postdiagnosis, patients were assigned to watchful waiting, radiation, hormonal therapy, hormonal + radiation, and surgery (may have received other treatments). Incremental costs for prostate cancer were the difference in costs for prostate cancer cases versus matched controls. Costs were divided into initial treatment (months -1 to 12), long-term (each 12 months thereafter), and total (months -1 to 60). Sensitivity analyses excluded the last 12 months of life. Results. A total of 13,769 prostate-cancer cases were matched to 13,769 noncancer controls. Watchful waiting had the lowest initial treatment ($4270) and 5-year total costs ($9130). Initial treatment costs were highest for hormonal + radiation ($17,474) and surgery ($15,197). At $26,896, 5-year total costs were highest for hormonal therapy only followed by hormonal + radiation ($25,097) and surgery ($19,214). After excluding the last 12 months of life, total costs were highest for hormonal + radiation ($23,488) and hormonal therapy ($23,199). Conclusions. Patterns of costs vary widely based on initial treatment. These data can inform patients and clinicians considering treatment options and policy makers interested in patterns of costs. Cancer 2010. © 2010 American Cancer Society. This study examined the short-term and long-term costs of prostate cancer treatment based on the initial treatment received for 13,769 men diagnosed with clinically localized prostate cancer. Patterns of costs varied widely based on initial treatment; 5-year total costs were $26,896 for hormonal therapy only, $25,097 for hormonal therapy plus radiation, $19,214 for surgery, $15,589 for radiation only, and $9130 for watchful waiting.

KW - costs

KW - health services

KW - patterns of care

KW - prostate cancer

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=78649605955&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649605955&partnerID=8YFLogxK

U2 - 10.1002/cncr.25517

DO - 10.1002/cncr.25517

M3 - Article

VL - 116

SP - 5391

EP - 5399

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 23

ER -